New trials, publications, preprints and grants on this target, month by month.
Trial
A Vaccine (STEMVAC) for Improving Survival in Patients With Triple-Negative Breast Cancer and Moderate or Extensive Residual Cancer Burden
1 Nov 2026· PHASE2 · NOT_YET_RECRUITING· CTGOV
Publication
The influence of LINC00511 and MDM2/MDM4 in lung carcinoma: Implications for immunological therapeutic strategies.
1 Nov 2026· Pakistan journal of pharmaceutical sciences· PUBMED
Publication
Correction: Strategic selection of MDM2 inhibitors enhances the efficacy of FAK inhibition in mesothelioma based on TP53 genotype.
26 Oct 2026· PloS one· PUBMED
Publication
Integrating AI-Based De Novo Design with Molecular Docking and Density Functional Theory Analysis to Optimize Flavonoid Scaffolds as p53-MDM2 Inhibitors for Triple-Negative Breast Cancer.
26 Oct 2026· Current topics in medicinal chemistry· PUBMED
Publication
Yindan Xinnaotong Soft Capsule Ameliorates Parkinson's Disease and is Associated with Modulation of the AKT/MDM2/p53 Pathway: Network Pharmacology, Molecular Docking, and Experimental Validation.
22 Oct 2026· CNS & neurological disorders drug targets· PUBMED
Publication
Case Report WIN-MTB-2024001 - WIN International Molecular Tumor Board: A 55-year-old male with glioblastoma exhibiting amplifications in MDM2 and EGFR.
16 Oct 2026· Oncotarget· PUBMED
Publication
Intimal sarcoma of the pulmonary vein with left atrial extension: a case report and diagnostic relevance of MDM2.
15 Oct 2026· Revista espanola de patologia : publicacion oficial de la Sociedad Espanola de Anatomia Patologica y de la Sociedad Espanola de Citologia· PUBMED
Publication
KT-253, a highly potent and selective MDM2 protein degrader, eliminates malignant myelofibrosis stem/progenitor cells.
6 Oct 2026· Leukemia· PUBMED
Publication
A Self-Assembled Affibody-Drug Conjugate Nanoagent for EGFR-Targeted Synergistic Codelivery of Exatecan and an MDM2 Inhibitory Peptide.
5 Oct 2026· Molecular pharmaceutics· PUBMED
Publication
Strategies for Overcoming Acquired Resistance of Tumor Cells to MDM2 Inhibitors.
1 Oct 2026· Biochemistry. Biokhimiia· PUBMED
Publication
A membrane-penetrating modified ascites-derived peptide, TAT-CPAP1, sensitizes TP53 wild-type ovarian cancer cells to platinum-based therapy through targeting the NOLC1-MDM2/MDM4 axis.
1 Oct 2026· Translational oncology· PUBMED
Publication
S100A1 Promotes MDM2-Mediated KLF15 Ubiquitination to Regulate ID1-Driven Tubular Injury in Diabetic Kidney Disease.
30 Sept 2026· FASEB journal : official publication of the Federation of American Societies for Experimental Biology· PUBMED
Publication
Correction: Resveratrol targeting MDM2/P53/PUMA axis to inhibit colonocyte apoptosis in DSS-induced ulcerative colitis mice.
25 Sept 2026· Frontiers in pharmacology· PUBMED
Publication
[Retracted] CALB1 enhances the interaction between p53 and MDM2, and inhibits the senescence of ovarian cancer cells.
25 Sept 2026· Molecular medicine reports· PUBMED
Publication
E3 Ubiquitin Ligase MDM2 Contributes to Proliferation, Migration/Invasion, Epithelial-Mesenchymal Transition, and Glycolytic Reprogramming in Lung Cancer via Ubiquitinating and Degrading MYH11 Protein.
31 Aug 2026· Molecular carcinogenesis· PUBMED
Publication
Driver genomic lesions in MDM2, CDK4, and JUN co-opt targetable super-enhancer networks to impose liposarcomagenic core regulatory circuitry.
31 Aug 2026· Journal of advanced research· PUBMED
Publication
Computational screening of natural product inhibitor stargeting the MDM2-p53 interaction: docking and molecular dynamics insights for retinoblastoma therapy.
15 Aug 2026· American journal of translational research· PUBMED
Publication
A First-in-Pediatric Study of ALRN-6924, a Novel Stapled-Peptide Dual MDM2/MDMX Inhibitor, for Children with Advanced Hematologic and Solid Malignancies.
14 Aug 2026· Clinical cancer research : an official journal of the American Association for Cancer Research· PUBMED
Publication
Retraction Note: Combined inhibition of AKT/mTOR and MDM2 enhances Glioblastoma Multiforme cell apoptosis and differentiation of cancer stem cells.
12 Aug 2026· Scientific reports· PUBMED
Publication
Dual MDM2 and PPARG regulatory axes mediate the antiepileptic effects of Gouteng: An integration of bioinformatics, network pharmacology, machine learning, molecular docking, and MD simulations.
10 Aug 2026· Neuropharmacology· PUBMED
Publication
MYC-driven BYSL overexpression promotes hepatocellular carcinoma by suppressing nucleolar stress and inactivating the RPL5/RPL11-MDM2-p53 pathway.
10 Aug 2026· Cellular signalling· PUBMED
Publication
MDM2 deletion and its associated p53 activation in subcutaneous white adipose tissue induce hepatic fibrosis via galectin-3 in a mouse model.
7 Aug 2026· Metabolism: clinical and experimental· PUBMED
Publication
Droplet Digital PCR Assessment of MDM2 Amplification in Liposarcoma Diagnosis and Prognosis: A French Single-Center Cohort Study.
2 Aug 2026· International journal of molecular sciences· PUBMED
Publication
Targeted degradation of P-TEFb via MDM2 substrate substitution collapses oncogenic transcriptional programs in MDM2-amplified cancers.
1 Aug 2026· Cell death & disease· PUBMED
Publication
LncDNAH5 Regulates Radiation Therapy-Induced Toxicity via MDM2-Mediated Degradation of TP53BP1.
1 Aug 2026· International journal of radiation oncology, biology, physics· PUBMED
Publication
Activating Sigma1R by fluoxetine suppresses neuronal ferroptosis in epilepsy by inhibiting MDM2-mediated GPX4 ubiquitination.
1 Aug 2026· Journal of advanced research· PUBMED
Publication
E3 Ubiquitin Ligase MDM2 Promotes Growth and CD8+ T Cell Dysfunction in Gastric Cancer Through Degradation of SST.
31 Jul 2026· Journal of gastroenterology and hepatology· PUBMED
Publication
Routine MDM2 FISH Testing and Preoperative Biopsy Reduces Recurrence Rate of Atypical Lipomatous Tumours.
29 Jul 2026· Journal of surgical oncology· PUBMED
Publication
hsa_circ_0008758 Activates the MDM2/FOXO3a/PGK1 Pathway Through the miR-361-3p/SPIN1 Axis to Promote the Warburg Effect of Non-Small Cell Lung Cancer.
22 Jul 2026· Tissue engineering and regenerative medicine· PUBMED
Publication
Transcriptomic Stratification Reveals an FRS2-Associated, Proliferation-Independent Phenotype in MDM2-High Sarcomas.
22 Jul 2026· Current oncology (Toronto, Ont.)· PUBMED